NCT07158151CompletedPhase 2
A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of RSS0393 Ointment in Adults With Mild to Moderate Atopic Dermatitis
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
This study is ongoing to explore the efficacy and safety of different strengths of RSS0393 ointment in adults with atopic dermatitis
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 168 (actual)
- First submitted
- 28 Aug 2025
- Start date
- 25 Sept 2025
- Primary completion date
- 10 Apr 2026
- Lead sponsor
- Reistone Biopharma Company Limited
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07158151
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 168
- From 25 Sept 2025 to the primary completion date, 10 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects who have received topical medication for psoriasis within 14 days before baseline, or systemic medication or phototherapy for psoriasis within 28 days before baseline, or biological agents for psoriasis within a specified time before baseline.
Other illness
- Diagnosis of other dermatologic diseases at screening.
- Subjects have other skin diseases or conditions that may affect the evaluation of the relevant endpoints of this study.
- Subjects with any other persistent active autoimmune disease.
Who the study is looking for
- Age ≥18 years old and ≤75 years old at screening.
- History of atopic dermatitis ≥ 6 months.
- BSA is between 3% and 20% (inclusive) and EASI score is ≥ 5 and vIGA-AD is 2 or 3.
- The subjects signed informed consent before any study-related procedures began.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dermatology Hospital of Southern Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.